Myocardial Revascularization

• 

  Subject Areas on Research

  • 1-Year Impact on Medical Practice and Clinical Outcomes of FFRCT: The ADVANCE Registry. 
  • 1985: left thoracotomy for reoperative coronary artery bypass procedures. 1993 update. 
  • 2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the diagnosis and management of patients with stable ischemic heart disease: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, and the American College of Physicians, American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. 
  • 2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS guideline for the diagnosis and management of patients with stable ischemic heart disease: a report of the American College of Cardiology Foundation/American Heart Association task force on practice guidelines, and the American College of Physicians, American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. 
  • 2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS guideline for the diagnosis and management of patients with stable ischemic heart disease: executive summary: a report of the American College of Cardiology Foundation/American Heart Association task force on practice guidelines, and the American College of Physicians, American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. 
  • 2021 ACC/AHA/SCAI Guideline for Coronary Artery Revascularization: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. 
  • 2021 ACC/AHA/SCAI Guideline for Coronary Artery Revascularization: Executive Summary: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. 
  • A Call to Action to Improve Outcomes in Women Undergoing Surgical Coronary Revascularization. 
  • A Phase 2, randomized, partially blinded, active-controlled study assessing the efficacy and safety of variable anticoagulation reversal using the REG1 system in patients with acute coronary syndromes: results of the RADAR trial. 
  • A comparison of mechanical and laser transmyocardial revascularization for induction of angiogenesis and arteriogenesis in chronically ischemic myocardium. 
  • A multicenter, randomized trial of percutaneous coronary intervention versus bypass surgery in high-risk unstable angina patients. The AWESOME (Veterans Affairs Cooperative Study #385, angina with extremely serious operative mortality evaluation) investigators from the Cooperative Studies Program of the Department of Veterans Affairs. 
  • A nationwide survey on perception, experience, and expectations of hybrid coronary revascularization among top-ranked US hospitals. 
  • A tale of two trials: a comparison of the post-acute coronary syndrome lipid-lowering trials A to Z and PROVE IT-TIMI 22. 
  • ACC/AATS/AHA/ASE/ASNC/SCAI/SCCT/STS 2016 Appropriate Use Criteria for Coronary Revascularization in Patients With Acute Coronary Syndromes: A Report of the American College of Cardiology Appropriate Use Criteria Task Force, American Association for Thoracic Surgery, American Heart Association, American Society of Echocardiography, American Society of Nuclear Cardiology, Society for Cardiovascular Angiography and Interventions, Society of Cardiovascular Computed Tomography, and the Society of Thoracic Surgeons. 
  • ACC/AATS/AHA/ASE/ASNC/SCAI/SCCT/STS 2017 Appropriate Use Criteria for Coronary Revascularization in Patients With Stable Ischemic Heart Disease : A Report of the American College of Cardiology Appropriate Use Criteria Task Force, American Association for Thoracic Surgery, American Heart Association, American Society of Echocardiography, American Society of Nuclear Cardiology, Society for Cardiovascular Angiography and Interventions, Society of Cardiovascular Computed Tomography, and Society of Thoracic Surgeons. 
  • ACC/AATS/AHA/ASE/ASNC/SCAI/SCCT/STS 2017 Appropriate Use Criteria for Coronary Revascularization in Patients With Stable Ischemic Heart Disease: A Report of the American College of Cardiology Appropriate Use Criteria Task Force, American Association for Thoracic Surgery, American Heart Association, American Society of Echocardiography, American Society of Nuclear Cardiology, Society for Cardiovascular Angiography and Interventions, Society of Cardiovascular Computed Tomography, and Society of Thoracic Surgeons. 
  • ACC/AHA Guidelines for Exercise Testing. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Exercise Testing). 
  • ACCF/ASE/ACEP/AHA/ASNC/SCAI/SCCT/SCMR 2008 appropriateness criteria for stress echocardiography: a report of the American College of Cardiology Foundation Appropriateness Criteria Task Force, American Society of Echocardiography, American College of Emergency Physicians, American Heart Association, American Society of Nuclear Cardiology, Society for Cardiovascular Angiography and Interventions, Society of Cardiovascular Computed Tomography, and Society for Cardiovascular Magnetic Resonance: endorsed by the Heart Rhythm Society and the Society of Critical Care Medicine. 
  • ACCF/SCAI/STS/AATS/AHA/ASNC 2009 Appropriateness Criteria for Coronary Revascularization : a report of the American College of Cardiology Foundation Appropriateness Criteria Task Force, Society for Cardiovascular Angiography and Interventions, Society of Thoracic Surgeons, American Association for Thoracic Surgery, American Heart Association, and the American Society of Nuclear Cardiology. Endorsed by the American Society of Echocardiography, the Heart Failure Society of America, and the Society of Cardiovascular Computed Tomography. 
  • ACCF/SCAI/STS/AATS/AHA/ASNC 2009 Appropriateness Criteria for Coronary Revascularization: A Report of the American College of Cardiology Foundation Appropriateness Criteria Task Force, Society for Cardiovascular Angiography and Interventions, Society of Thoracic Surgeons, American Association for Thoracic Surgery, American Heart Association, and the American Society of Nuclear Cardiology: Endorsed by the American Society of Echocardiography, the Heart Failure Society of America, and the Society of Cardiovascular Computed Tomography. 
  • ACCF/SCAI/STS/AATS/AHA/ASNC 2009 Appropriateness Criteria for Coronary Revascularization: a report by the American College of Cardiology Foundation Appropriateness Criteria Task Force, Society for Cardiovascular Angiography and Interventions, Society of Thoracic Surgeons, American Association for Thoracic Surgery, American Heart Association, and the American Society of Nuclear Cardiology Endorsed by the American Society of Echocardiography, the Heart Failure Society of America, and the Society of Cardiovascular Computed Tomography. 
  • ACCF/SCAI/STS/AATS/AHA/ASNC/HFSA/SCCT 2012 Appropriate use criteria for coronary revascularization focused update: a report of the American College of Cardiology Foundation Appropriate Use Criteria Task Force, Society for Cardiovascular Angiography and Interventions, Society of Thoracic Surgeons, American Association for Thoracic Surgery, American Heart Association, American Society of Nuclear Cardiology, and the Society of Cardiovascular Computed Tomography. 
  • ACCF/SCAI/STS/AATS/AHA/ASNC/HFSA/SCCT 2012 appropriate use criteria for coronary revascularization focused update: a report of the American College of Cardiology Foundation Appropriate Use Criteria Task Force, Society for Cardiovascular Angiography and Interventions, Society of Thoracic Surgeons, American Association for Thoracic Surgery, American Heart Association, American Society of Nuclear Cardiology, and the Society of Cardiovascular Computed Tomography. 
  • Achievement of dual low-density lipoprotein cholesterol and high-sensitivity C-reactive protein targets more frequent with the addition of ezetimibe to simvastatin and associated with better outcomes in IMPROVE-IT. 
  • Acute Cardiovascular Care Association position statement for the diagnosis and treatment of patients with acute myocardial infarction complicated by cardiogenic shock: A document of the Acute Cardiovascular Care Association of the European Society of Cardiology. 
  • Acute and long-term cost implications of coronary stenting. 
  • Acute coronary care in the elderly, part II: ST-segment-elevation myocardial infarction: a scientific statement for healthcare professionals from the American Heart Association Council on Clinical Cardiology: in collaboration with the Society of Geriatric Cardiology. 
  • Acute coronary syndromes: introducing new therapies into established guidelines. 
  • Acute myocardial infarction complicated by atrial fibrillation in the elderly: prevalence and outcomes. 
  • Acute myocardial infarction: safety of cardiac MR imaging after percutaneous revascularization with stents. 
  • Advanced coronary artery disease: Appropriate end points for trials of novel therapies. 
  • After myocardial infarction. How to determine future risk and what to do then. 
  • Age, knowledge, preferences, and risk tolerance for invasive cardiac care. 
  • Aggressive therapy of acute MI in the elderly. 
  • Alprazolam withdrawal presenting as delirium after cardiac surgery. 
  • American College of Cardiology/Society for Cardiac Angiography and Interventions Clinical Expert Consensus Document on cardiac catheterization laboratory standards. A report of the American College of Cardiology Task Force on Clinical Expert Consensus Documents. 
  • Ameroid constrictor versus hydraulic occluder: creation of hibernating myocardium. 
  • An age- and sex-specific gene expression score is associated with revascularization and coronary artery disease: Insights from the Prospective Multicenter Imaging Study for Evaluation of Chest Pain (PROMISE) trial. 
  • Anger proneness predicts coronary heart disease risk: prospective analysis from the atherosclerosis risk in communities (ARIC) study. 
  • Angina and Future Cardiovascular Events in Stable Patients With Coronary Artery Disease: Insights From the Reduction of Atherothrombosis for Continued Health (REACH) Registry. 
  • Angiographic validation of the American College of Cardiology Foundation-the Society of Thoracic Surgeons Collaboration on the Comparative Effectiveness of Revascularization Strategies study. 
  • Appropriate Use Criteria for Coronary Revascularization and Trends in Utilization, Patient Selection, and Appropriateness of Percutaneous Coronary Intervention. 
  • Appropriateness of percutaneous coronary intervention. 
  • Are international differences in the outcomes of acute coronary syndromes apparent or real? A multilevel analysis. 
  • Assessing the economic attractiveness of coronary artery revascularization in chronic kidney disease patients. 
  • Association of early physician follow-up and 30-day readmission after non-ST-segment-elevation myocardial infarction among older patients. 
  • Association of hospital myocardial infarction volume with adherence to American College of Cardiology/American Heart Association performance measures: Insights from the National Cardiovascular Data Registry. 
  • Association of revascularisation with low mortality in non-ST elevation acute coronary syndrome, a report from GUSTO IV-ACS. 
  • Baseline Characteristics and Risk Profiles of Participants in the ISCHEMIA Randomized Clinical Trial. 
  • Baseline Low-Density Lipoprotein Cholesterol and Clinical Outcomes of Combining Ezetimibe With Statin Therapy in IMPROVE-IT. 
  • Biomarkers: Troponin testing--risk stratification to stratified medicine. 
  • Bivalirudin provides rapid, effective, and reliable anticoagulation during off-pump coronary revascularization: results of the "EVOLUTION OFF" trial. 
  • CLINICAL PRACTICE. Chronic Stable Angina. 
  • Canadian-American differences in the management of acute coronary syndromes in the GUSTO IIb trial: one-year follow-up of patients without ST-segment elevation. Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO) II Investigators. 
  • Cardiac allograft vasculopathy after heart transplantation: current prevention and treatment strategies. 
  • Cardiac mortality in patients randomised to elective coronary revascularisation plus medical therapy or medical therapy alone: a systematic review and meta-analysis. 
  • Cardiac myocyte p38α kinase regulates angiogenesis via myocyte-endothelial cell cross-talk during stress-induced remodeling in the heart. 
  • Cerebral embolization during transmyocardial laser revascularization. 
  • Changes in mortality after myocardial revascularization in the elderly. The national Medicare experience. 
  • Characteristics and long-term outcomes of percutaneous revascularization of unprotected left main coronary artery stenosis in the United States: a report from the National Cardiovascular Data Registry, 2004 to 2008. 
  • Characterization and outcomes of women and men with non-ST-segment elevation myocardial infarction and nonobstructive coronary artery disease: results from the Can Rapid Risk Stratification of Unstable Angina Patients Suppress Adverse Outcomes with Early Implementation of the ACC/AHA Guidelines (CRUSADE) quality improvement initiative. 
  • Characterization of myocardial infarction as an end point in two large trials of acute coronary syndromes. 
  • Choosing between percutaneous coronary intervention and coronary artery bypass grafting for patients with multivessel disease: what can we learn from the Arterial Revascularization Therapy Study (ARTS)? 
  • Claims-based cardiovascular outcome identification for clinical research: Results from 7 large randomized cardiovascular clinical trials. 
  • Clinical Events After Deferral of LAD Revascularization Following Physiological Coronary Assessment. 
  • Clinical and angiographic assessment of complex mammary artery bypass grafting. 
  • Clinical and research issues regarding chronic advanced coronary artery disease part II: Trial design, outcomes, and regulatory issues. 
  • Clinical and research issues regarding chronic advanced coronary artery disease: part I: Contemporary and emerging therapies. 
  • Clinical characteristics and outcomes of patients with angina and heart failure in the CHARM (Candesartan in Heart Failure Assessment of Reduction in Mortality and Morbidity) Programme. 
  • Clinical outcome of a cohort of patients eligible for therapeutic angiogenesis or transmyocardial revascularization. 
  • Clinical outcomes in real-world patients with small vessel disease treated with XIENCE V® everolimus-eluting stents: one year results from the XIENCE V® USA condition of approval post-market study. 
  • Clinical outcomes of fractional flow reserve by computed tomographic angiography-guided diagnostic strategies vs. usual care in patients with suspected coronary artery disease: the prospective longitudinal trial of FFR(CT): outcome and resource impacts study. 
  • Clinical outcomes of hybrid coronary revascularization versus coronary artery bypass surgery in patients with diabetes mellitus. 
  • Clinical outcomes of therapeutic agents that block the platelet glycoprotein IIb/IIIa integrin in ischemic heart disease. 
  • Clinical perspectives on reperfusion injury in acute myocardial infarction. 
  • Clopidogrel use After Myocardial Revascularization: Prevalence, Predictors, and One-Year Survival Rate. 
  • Cochrane corner: complete versus culprit-only revascularisation in ST segment elevation myocardial infarction with multivessel disease. 
  • Combined TMR and mitral valve replacement via left thoracotomy. 
  • Combined use of warfarin and oral P2Y12 inhibitors in patients with atrial fibrillation and acute coronary syndrome. 
  • Comparative Effectiveness of Hybrid Coronary Revascularization vs Coronary Artery Bypass Grafting. 
  • Comparative Efficacy of Coronary Revascularization Procedures for Multivessel Coronary Artery Disease in Patients With Chronic Kidney Disease. 
  • Comparison of Days Alive Out of Hospital With Initial Invasive vs Conservative Management: A Prespecified Analysis of the ISCHEMIA Trial. 
  • Comparison of Delay Times from Symptom Onset to Medical Contact in Blacks Versus Whites With Acute Myocardial Infarction. 
  • Comparison of International Guidelines for Assessment of Suspected Stable Angina: Insights From the PROMISE and SCOT-HEART. 
  • Comparison of hybrid coronary revascularization versus coronary artery bypass grafting in patients≥65 years with multivessel coronary artery disease. 
  • Comparison of the HEART and TIMI Risk Scores for Suspected Acute Coronary Syndrome in the Emergency Department. 
  • Complete revascularisation in ST-elevation myocardial infarction and multivessel disease: meta-analysis of randomised controlled trials. 
  • Complete reversal of ischemic wall motion abnormalities by combined use of gene therapy with transmyocardial laser revascularization. 
  • Complete versus culprit-only revascularisation in ST elevation myocardial infarction with multi-vessel disease. 
  • Contemporary utilization and outcomes of intra-aortic balloon counterpulsation in acute myocardial infarction: the benchmark registry. 
  • Contribution of individual components to composite end points in contemporary cardiovascular randomized controlled trials. 
  • Controversies in cardiovascular MR imaging: T2-weighted imaging should not be used to delineate the area at risk in ischemic myocardial injury. 
  • Coronary Revascularization During Heart Regeneration Is Regulated by Epicardial and Endocardial Cues and Forms a Scaffold for Cardiomyocyte Repopulation. 
  • Coronary revascularization and circulatory support strategies in patients with myocardial infarction, multi-vessel coronary artery disease, and cardiogenic shock: Insights from an international survey. 
  • Coronary revascularization in lung transplant recipients with concomitant coronary artery disease. 
  • Coronary revascularization rather than cardiac transplantation for chronic ischemic cardiomyopathy. 
  • Cost and cost-effectiveness of an early invasive vs conservative strategy for the treatment of unstable angina and non-ST-segment elevation myocardial infarction. 
  • Cost effectiveness of abciximab during routine medical practice. 
  • Cost estimates for treatment of cardiac ischemia (from the Asymptomatic Cardiac Ischemia Pilot [ACIP] study). 
  • Cost-effectiveness Analysis of Anatomic vs Functional Index Testing in Patients With Low-Risk Stable Chest Pain. 
  • Cost-effectiveness of coronary stenting and abciximab for patients with acute myocardial infarction: results from the CADILLAC (Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications) trial. 
  • Culprit-only or multivessel revascularization in patients with acute coronary syndromes: an American College of Cardiology National Cardiovascular Database Registry report. 
  • Current State of Stem Cell Therapy for Ischemic Heart Disease. 
  • Current landscape of hybrid revascularization: A report from the NCDR CathPCI Registry. 
  • Defining heart failure end points in ST-segment elevation myocardial infarction trials: integrating past experiences to chart a path forward. 
  • Design and methodology of the Occluded Artery Trial (OAT). 
  • Diagnosing and managing unstable angina. Agency for Health Care Policy and Research. 
  • Diagnosis, incidence, and clinical significance of early postoperative ischemia after transmyocardial laser revascularization. 
  • Differences in treatment patterns and outcomes between Hispanics and non-Hispanic Whites treated for ST-segment elevation myocardial infarction: results from the NCDR ACTION Registry-GWTG. 
  • Differential treatment benefit of platelet glycoprotein IIb/IIIa inhibition with percutaneous coronary intervention versus medical therapy for acute coronary syndromes: exploration of methods. 
  • Discharge timing and outcomes after uncomplicated non-ST-segment elevation acute myocardial infarction. 
  • Does coronary surgery prolong life in comparison with medical management? 
  • Does prior coronary angioplasty affect outcomes of surgical coronary revascularization? Insights from the STICH trial. 
  • Downstream clinical consequences of stress cardiovascular magnetic resonance based on appropriate use criteria. 
  • Downstream procedures and outcomes after stress testing for chest pain without known coronary artery disease in the United States. 
  • Dual antiplatelet therapy in patients with diabetes and acute coronary syndromes managed without revascularization. 
  • ESC Forum on Drug Eluting Stents European Heart House, Nice, 27-28 September 2007. 
  • ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: The Task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC). 
  • Early intervention: which patients and how early? 
  • Early invasive strategy for acute coronary syndromes without persistent ST-segment elevation: has the time come for 'drive-through' angiography? 
  • Early mortality of acute myocardial infarction in patients with and without prior coronary revascularization surgery. A Coronary Artery Surgery Study Registry Study. 
  • Early routine percutaneous coronary intervention after fibrinolysis vs. standard therapy in ST-segment elevation myocardial infarction: a meta-analysis. 
  • Echocardiography for the assessment of myocardial viability. 
  • Economic assessment of platelet glycoprotein IIb/IIIa receptor blockade with abciximab and low-dose heparin during percutaneous coronary revascularization: results from the EPILOG randomized trial. Evaluation in PTCA to Improve Long-term Outcome with abciximab GP IIb/IIIa blockade. 
  • Economic implications of the prophylactic use of intraaortic balloon counterpulsation in the setting of acute myocardial infarction. The Randomized IABP Study Group. Intraaortic Balloon Pump. 
  • Edifoligide and long-term outcomes after coronary artery bypass grafting: PRoject of Ex-vivo Vein graft ENgineering via Transfection IV (PREVENT IV) 5-year results. 
  • Effect of age on efficacy and safety of vorapaxar in patients with non-ST-segment elevation acute coronary syndrome: Insights from the Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRACER) trial. 
  • Effect of atorvastatin in elderly patients with a recent stroke or transient ischemic attack. 
  • Effect of cardiac rehabilitation on functional outcomes after coronary revascularization. 
  • Effect of gender on the outcomes of contemporary percutaneous coronary intervention. 
  • Effect of once-weekly exenatide on hospitalization for acute coronary syndrome or coronary revascularization in patients with type 2 diabetes mellitus. 
  • Effect of the Presence and Type of Angina on Cardiovascular Events in Patients Without Known Coronary Artery Disease Referred for Elective Coronary Angiography. 
  • Effects of Ranolazine on Angina and Quality of Life After Percutaneous Coronary Intervention With Incomplete Revascularization: Results From the Ranolazine for Incomplete Vessel Revascularization (RIVER-PCI) Trial. 
  • Efficacy of abciximab readministration in coronary intervention. 
  • Estimating the real-world performance of the PROMISE minimal-risk tool. 
  • Evaluation of myocardial viability by MRI. 
  • Evolving revascularization approaches for myocardial ischemia. 
  • Fondaparinux with UnfracTionated heparin dUring Revascularization in Acute coronary syndromes (FUTURA/OASIS 8): a randomized trial of intravenous unfractionated heparin during percutaneous coronary intervention in patients with non-ST-segment elevation acute coronary syndromes initially treated with fondaparinux. 
  • From HIRMIT to the Cape May Lighthouse. Revascularization reconsidered in very high risk patients at the Duke Heart Center. 
  • From controlled trials to clinical practice: monitoring transmyocardial revascularization use and outcomes. 
  • Fundamental concepts in myocardial viability assessment revisited: when knowing how much is "alive" is not enough. 
  • Gender differences in outcomes after primary angioplasty versus primary stenting with and without abciximab for acute myocardial infarction: results of the Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) trial. 
  • HEART Failure? Episodes of Missed Major Cardiac Events When Applying the HEART Pathway to an Observation Unit Population. 
  • Health Status and Clinical Outcomes in Older Adults With Chronic Coronary Disease: The ISCHEMIA Trial. 
  • Health-Status Outcomes with Invasive or Conservative Care in Coronary Disease. 
  • Higher rates of coronary angiography and revascularization following myocardial infarction may be associated with greater survival in the United States than in Canada. The CARS Investigators (Coumadin/Aspirin Reinfarction Study). 
  • Hospital patterns of medical management strategy use for patients with non-ST-elevation myocardial infarction and 3-vessel or left main coronary artery disease. 
  • How can we optimize the processes of care for acute coronary syndromes to improve outcomes? 
  • Impact of Procedural Bleeding in Peripheral Artery Disease: An Analysis From EUCLID Trial. 
  • Impact of Proton Pump Inhibitor Use on the Comparative Effectiveness and Safety of Prasugrel Versus Clopidogrel: Insights From the Treatment With Adenosine Diphosphate Receptor Inhibitors: Longitudinal Assessment of Treatment Patterns and Events After Acute Coronary Syndrome (TRANSLATE-ACS) Study. 
  • Impact of an interactive video on decision making of patients with ischemic heart disease. 
  • Impact of body mass index on outcome after percutaneous coronary intervention (the obesity paradox). 
  • Impact of candesartan on nonfatal myocardial infarction and cardiovascular death in patients with heart failure. 
  • Impact of choice of imaging modality accompanying outpatient exercise stress testing on outcomes and resource use after revascularization for acute coronary syndromes. 
  • Impact of chronic antiplatelet therapy before hospitalization on ischemic and bleeding events in invasively managed patients with acute coronary syndromes: the ACUITY trial. 
  • Impact of combined pharmacologic treatment with clopidogrel and a statin on outcomes of patients with non-ST-segment elevation acute coronary syndromes: perspectives from a large multinational registry. 
  • Impact of diabetes mellitus on clinical characteristics, management, and in-hospital outcomes in patients with acute myocardial infarction (from the NCDR). 
  • Impact of different patterns of invasive care on quality of life outcomes in patients with non-ST elevation acute coronary syndrome: results from the GUSTO-IIb Canada-United States substudy. 
  • Impact of ethnicity and gender differences on angiographic coronary artery disease prevalence and in-hospital mortality in the American College of Cardiology-National Cardiovascular Data Registry. 
  • Impact of home warfarin use on treatment patterns and bleeding complications for patients with non-ST-segment elevation acute coronary syndromes: observations from the CRUSADE quality improvement initiative. 
  • Impact of left ventricular ejection fraction on clinical outcomes over five years after infarct-related coronary artery recanalization (from the Occluded Artery Trial [OAT]). 
  • Impact of managed care on the treatment, costs, and outcomes of fee-for-service Medicare patients with acute myocardial infarction. 
  • Impact of smoking status on platelet function and clinical outcomes with prasugrel vs. clopidogrel in patients with acute coronary syndromes managed without revascularization: Insights from the TRILOGY ACS trial. 
  • Impact of thienopyridine administration prior to primary stenting in acute myocardial infarction. 
  • Impact of time of presentation on the care and outcomes of acute myocardial infarction. 
  • Implantable Cardioverter Defibrillator Utilization and Mortality Among Patients ≥65 Years of Age With a Low Ejection Fraction After Coronary Revascularization. 
  • Implantable cardioverter defibrillator therapy in patients with prior coronary revascularization in the Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT). 
  • Improved perfusion and contractile reserve after transmyocardial laser revascularization in a model of hibernating myocardium. 
  • Improving clinical outcomes by reducing bleeding in patients with non-ST-elevation acute coronary syndromes. 
  • Improving quality of life after cardiogenic shock: do more revascularization! 
  • In-hospital revascularization and one-year outcome of acute coronary syndrome patients stratified by the GRACE risk score. 
  • Incidence and impact of totally occluded culprit coronary arteries in patients presenting with non-ST-segment elevation myocardial infarction. 
  • Incidence, timing, and type of first and recurrent ischemic events in patients with and without peripheral artery disease after an acute coronary syndrome. 
  • Incidental moderate mitral regurgitation in patients undergoing coronary artery bypass grafting: update on guidelines and key randomized trials. 
  • Induction of angiogenesis after TMR: a comparison of holmium: YAG, CO2, and excimer lasers. 
  • Influence of coronary artery disease and coronary revascularization status on outcomes in patients with acute heart failure syndromes: a report from OPTIMIZE-HF (Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure). 
  • Influence of hypothermic cardiopulmonary bypass on atrial natriuretic factor levels. 
  • Influence of insurance type on the use of procedures, medications and hospital outcome in patients with unstable angina: results from the GUARANTEE Registry. Global Unstable Angina Registry and Treatment Evaluation. 
  • Influence of racial disparities in procedure use on functional status outcomes among patients with coronary artery disease. 
  • Influence of the Angioplasty Revascularization Investigation National Heart, Lung, and Blood Institute Diabetic Clinical Alert on practice patterns: results from the National Cardiovascular Network Database. 
  • Influence of transfer-in rates on quality of care and outcomes at receiving hospitals in patients with non-ST-segment elevation myocardial infarction. 
  • Initial Invasive or Conservative Strategy for Stable Coronary Disease. 
  • Initial experience with multivessel percutaneous coronary intervention during mechanical reperfusion for acute myocardial infarction. 
  • International Study of Comparative Health Effectiveness with Medical and Invasive Approaches (ISCHEMIA) trial: Rationale and design. 
  • International Study of Comparative Health Effectiveness with Medical and Invasive Approaches-Chronic Kidney Disease (ISCHEMIA-CKD): Rationale and design. 
  • International differences in in-hospital revascularization and outcomes following acute myocardial infarction: a multilevel analysis of patients in ASSENT-2. 
  • International variation in invasive care of the elderly with acute coronary syndromes. 
  • Intracoronary thrombus and complex morphology in unstable angina. Relation to timing of angiography and in-hospital cardiac events. 
  • Intraoperative contrast echocardiography. 
  • Is there a bias against performing coronary revascularization in women? 
  • Lack of progress in cardiogenic shock: lessons from the GUSTO trials. 
  • Left ventricular long axis function assessed during cine-cardiovascular magnetic resonance is an independent predictor of adverse cardiac events. 
  • Long-Term Mortality of Older Patients With Acute Myocardial Infarction Treated in US Clinical Practice. 
  • Long-term economic outcomes associated with intensive versus moderate lipid-lowering therapy in coronary artery disease: results from the Treating to New Targets (TNT) Trial. 
  • Long-term mortality of patients with acute myocardial infarction in the United States and Canada: comparison of patients enrolled in Global Utilization of Streptokinase and t-PA for Occluded Coronary Arteries (GUSTO)-I. 
  • Long-term outcome and impact of surgery on adults with coronary arteries originating from the opposite coronary cusp. 
  • Long-term outcomes after transmyocardial revascularization. 
  • Long-term outcomes for women versus men with unstable angina/non-ST-segment elevation myocardial infarction managed medically without revascularization: insights from the TaRgeted platelet Inhibition to cLarify the Optimal strateGy to medicallY manage Acute Coronary Syndromes trial. 
  • Long-term protection from myocardial ischemic events in a randomized trial of brief integrin beta3 blockade with percutaneous coronary intervention. EPIC Investigator Group. Evaluation of Platelet IIb/IIIa Inhibition for Prevention of Ischemic Complication. 
  • Loss of short-term symptomatic benefit in patients with an occluded infarct artery is unrelated to non-protocol revascularization: results from the Occluded Artery Trial (OAT). 
  • Low molecular weight heparin (dalteparin) compared to unfractionated heparin as an adjunct to rt-PA (alteplase) for improvement of coronary artery patency in acute myocardial infarction-the ASSENT Plus study. 
  • Low-molecular-weight heparin compared with unfractionated heparin for patients with non-ST-segment elevation acute coronary syndromes treated with glycoprotein IIb/IIIa inhibitors: results from the CRUSADE initiative. 
  • Lymphatic angiogenesis induced by transmyocardial laser revascularization. 
  • Management and outcomes of patients presenting with STEMI by use of chronic oral anticoagulation: results from the GRACE registry. 
  • Management of Patients with Asymptomatic and Symptomatic Carotid Artery Disease: Update on Anti-Thrombotic Therapy. 
  • Management of cardiogenic shock. 
  • Medicaid, managed care, and the care of patients hospitalized for acute myocardial infarction. 
  • Medical economics and the assessment of value in cardiovascular medicine: Part II. 
  • Meta-analysis of survival and relief of angina pectoris after transmyocardial revascularization. 
  • Mitral gradients and frequency of recurrence of mitral regurgitation after ring annuloplasty for ischemic mitral regurgitation. 
  • Mode of hospital presentation in patients with non-ST-elevation myocardial infarction: implications for strategic management. 
  • Mortality benefit of beta blockade in patients with acute coronary syndromes undergoing coronary intervention: pooled results from the Epic, Epilog, Epistent, Capture and Rapport Trials. 
  • Myocardial thinning in patients with coronary artery disease--reply. 
  • Myonecrosis after revascularization procedures. 
  • Neovascularization after transmyocardial laser revascularization in a model of chronic ischemia. 
  • Noninvasive FFR Derived From Coronary CT Angiography: Management and Outcomes in the PROMISE Trial. 
  • Obesity in patients with non-ST-segment elevation acute coronary syndromes: results from the SYNERGY trial. 
  • Off-pump coronary artery bypass grafting. Excellent results in a group of selected high-risk patients. 
  • Optimal timing of coronary invasive strategy in non-ST-segment elevation acute coronary syndromes: a systematic review and meta-analysis. 
  • Optimizing use of revascularization and clinical outcomes in ST-elevation myocardial infarction: insights from the GUSTO-V trial. 
  • Outcomes According to Cardiac Catheterization Referral and Clopidogrel Use Among Medicare Patients With Non-ST-Segment Elevation Myocardial Infarction Discharged Without In-hospital Revascularization. 
  • Outcomes Among Patients Transferred for Revascularization With Impella for Acute Myocardial Infarction With Cardiogenic Shock from the cVAD Registry. 
  • Outcomes after planned invasive or conservative treatment strategy in patients with non-ST-elevation acute coronary syndrome and a normal value of high sensitivity troponin at randomisation: A Platelet Inhibition and Patient Outcomes (PLATO) trial biomarker substudy. 
  • Outcomes of Patients Receiving Downstream Revascularization After Initial Medical Management for Non-ST-Segment Elevation Acute Coronary Syndromes (From the TRILOGY ACS Trial). 
  • Outcomes of second revascularization procedures after stent implantation. 
  • Outcomes with the polymer-based paclitaxel-eluting TAXUS stent in patients with diabetes mellitus: the TAXUS-IV trial. 
  • Outpatient versus observation/inpatient management of emergency department patients rapidly ruled-out for acute myocardial infarction: Findings from the HIGH-US study. 
  • PREPARED Study: A Study of Shared Decision-Making for Coronary Artery Disease. 
  • Part I: Identifying holes in the safety net. 
  • Patient outcomes after fibrinolytic therapy for acute myocardial infarction at hospitals with and without coronary revascularization capability. 
  • Patterns of transfer for patients with non-ST-segment elevation acute coronary syndrome from community to tertiary care hospitals. 
  • Percutaneous coronary revascularisation: is it ever worth what it costs? 
  • Percutaneous intervention, surgery, and medical therapy: a perspective from the Duke Databank for Cardiovascular Diseases. 
  • Perioperative morbidity and mortality after transmyocardial laser revascularization: incidence and risk factors for adverse events. 
  • Persistent angina pectoris in ischaemic cardiomyopathy: increased rehospitalization and major adverse cardiac events. 
  • Platelet glycoprotein IIb/IIIa integrin blockade with eptifibatide in coronary stent intervention: the ESPRIT trial: a randomized controlled trial. 
  • Pooled analysis of adverse event collection from 4 acute coronary syndrome trials. 
  • Potential relief for refractory angina. 
  • Prediction of enzymatic infarct size in ST-segment elevation myocardial infarction. 
  • Predictors of long-term clinical endpoints in patients with refractory angina. 
  • Preferences for cardiac tests and procedures may partially explain sex but not race disparities. 
  • Prevalence of regional myocardial thinning and relationship with myocardial scarring in patients with coronary artery disease. 
  • Prior polyvascular disease: risk factor for adverse ischaemic outcomes in acute coronary syndromes. 
  • Prognostic importance of new small Q waves following non-ST-elevation acute coronary syndromes. 
  • Prognostic value of angiographic lesion complexity in patients with acute coronary syndromes undergoing percutaneous coronary intervention (from the acute catheterization and urgent intervention triage strategy trial). 
  • Promise of combined low-molecular-weight heparin and platelet glycoprotein IIb/IIIa inhibition: results from Platelet IIb/IIIa Antagonist for the Reduction of Acute coronary syndrome events in a Global Organization Network B (PARAGON B). 
  • Prospects for cardiovascular research. 
  • Putting the Acute Coronary Syndrome in Context After 80 Years of Age. 
  • Quality of care and in-hospital outcomes in patients with coronary heart disease in rural and urban hospitals (from Get With the Guidelines-Coronary Artery Disease Program). 
  • Quality of care for patients with acute coronary syndromes as a function of hospital revascularization capability: Insights from get with the guidelines-CAD. 
  • Quality of life after coronary revascularization in the United States and Canada. 
  • Quantitative echocardiographic assessment of regional wall motion and left ventricular asynchrony with color kinesis in cardiac surgery patients. 
  • Racial differences in long-term outcomes among black and white patients with drug-eluting stents. 
  • Racial differences in long-term survival among patients with coronary artery disease. 
  • Racial impact of diurnal variations in blood pressure on cardiovascular events in chronic kidney disease. 
  • Racial variations in treatment and outcomes of black and white patients with high-risk non-ST-elevation acute coronary syndromes: insights from CRUSADE (Can Rapid Risk Stratification of Unstable Angina Patients Suppress Adverse Outcomes With Early Implementation of the ACC/AHA Guidelines?). 
  • Radionuclide viability testing: should it affect treatment strategy in patients with cardiomyopathy and significant coronary artery disease? 
  • Randomised placebo-controlled trial of effect of eptifibatide on complications of percutaneous coronary intervention: IMPACT-II. Integrilin to Minimise Platelet Aggregation and Coronary Thrombosis-II. 
  • Randomized comparison of the clinical outcome of single versus multiple arterial grafts: the ROMA trial-rationale and study protocol. 
  • Randomized, blinded trial comparing fondaparinux with unfractionated heparin in patients undergoing contemporary percutaneous coronary intervention: Arixtra Study in Percutaneous Coronary Intervention: a Randomized Evaluation (ASPIRE) Pilot Trial. 
  • Ranolazine in patients with incomplete revascularisation after percutaneous coronary intervention (RIVER-PCI): a multicentre, randomised, double-blind, placebo-controlled trial. 
  • Rationale and clinical evidence for the use of GP IIb/IIIa inhibitors in acute coronary syndromes. 
  • Rationale and design of the Statins Evaluation in Coronary procedUres and REvascularization: The SECURE-PCI Trial. 
  • Real-world clinical utility and impact on clinical decision-making of coronary computed tomography angiography-derived fractional flow reserve: lessons from the ADVANCE Registry. 
  • Reassessment of Cardiac Function and Implantable Cardioverter-Defibrillator Use Among Medicare Patients With Low Ejection Fraction After Myocardial Infarction. 
  • Recent trends in the care of patients with non-ST-segment elevation acute coronary syndromes: insights from the CRUSADE initiative. 
  • Reducing system delays in treatment of ST elevation myocardial infarction and confronting the challenges of late presentation in low and middle-income countries. 
  • Regional cardiac sympathetic innervation early and late after transmyocardial laser revascularization. 
  • Relation of Age and Health-Related Quality of Life to Invasive Versus Ischemia-Guided Management of Patients with Non-ST Elevation Myocardial Infarction. 
  • Relation of early saphenous vein graft failure to outcomes following coronary artery bypass surgery. 
  • Relationship Between Optimism and Outcomes in Patients With Chronic Angina Pectoris. 
  • Response to letter regarding article, "surgical revascularization is associated with maximal survival in patients with ischemic mitral regurgitation: a 20-year experience". 
  • Results with a selective revascularization strategy for left subclavian artery coverage during thoracic endovascular aortic repair. 
  • Revascularization in patients with coronary artery disease, left ventricular dysfunction, and viability: a meta-analysis. 
  • Risk Factor Burden and Long-Term Prognosis of Patients With Premature Coronary Artery Disease. 
  • Risk adjustment for in-hospital mortality of contemporary patients with acute myocardial infarction: the acute coronary treatment and intervention outcomes network (ACTION) registry-get with the guidelines (GWTG) acute myocardial infarction mortality model and risk score. 
  • Risk-benefit trade-offs in revascularisation choices. 
  • Role of nuclear imaging after coronary revascularization. 
  • Ruminating on OAT: is the case closed? 
  • Safety and efficacy of drug-eluting stents in older patients with chronic kidney disease: a report from the linked CathPCI Registry-CMS claims database. 
  • Safety of the Deferral of Coronary Revascularization on the Basis of Instantaneous Wave-Free Ratio and Fractional Flow Reserve Measurements in Stable Coronary Artery Disease and Acute Coronary Syndromes. 
  • Selection of patients for coronary angiography and coronary revascularization early after myocardial infarction: is there evidence for a gender bias? 
  • Sensitive troponin I assay in patients with suspected acute coronary syndrome. 
  • Sex bias in cardiovascular care: should women be treated more like men? 
  • Sex-Based Differences in Presentation, Treatment, and Complications Among Older Adults Hospitalized for Acute Myocardial Infarction: The SILVER-AMI Study. 
  • Shifting the open-artery hypothesis downstream: the quest for optimal reperfusion. 
  • Short and long term effect of adjunctive intra-aortic balloon pump use for patients undergoing high risk reperfusion therapy: a meta-analysis of 10 international randomised trials. 
  • Spontaneous MI After Non-ST-Segment Elevation Acute Coronary Syndrome Managed Without Revascularization: The TRILOGY ACS Trial. 
  • Strategies to attenuate pathological remodeling in heart failure. 
  • Streptokinase versus alteplase in acute myocardial infarction. 
  • Stress imaging use and repeat revascularization among medicare patients with high-risk coronary artery disease. 
  • Surgeon judgment and utility of transit time flow probes in coronary artery bypass grafting surgery. 
  • Surgical revascularization is associated with maximal survival in patients with ischemic mitral regurgitation: a 20-year experience. 
  • Tardy Pardee: moving medical effectiveness to the forefront. 
  • Temporal Trends in Prevalence and Prognostic Implications of Comorbidities Among Patients With Acute Decompensated Heart Failure: The ARIC Study Community Surveillance. 
  • Temporal Trends in the Clinical Acuity of Patients with ST-Segment Elevation Myocardial Infarction. 
  • Temporal evolution in the management of acute ST elevation myocardial infarction: the seven-year GUSTO experience from canada and the united states. The North American GUSTO-I and GUSTO-III investigators. 
  • Temporal trends and predictors in the use of aldosterone antagonists post-acute myocardial infarction. 
  • Temporal trends in target vessel revascularization in clinical practice: long-term outcomes following coronary stenting from the Duke Database for Cardiovascular Disease. 
  • The Association of Transfer Rate From Hospitals Without Revascularization Capabilities and Mortality Risk for Older Non-ST-Segment Elevation Myocardial Infarction Patients. 
  • The Contemporary Use of Angiography and Revascularization Among Patients With Non-ST-Segment Elevation Myocardial Infarction in the United States Compared With South Korea. 
  • The effect of dementia on outcomes and process of care for Medicare beneficiaries admitted with acute myocardial infarction. 
  • The effects of coronary revascularization on left ventricular function in ischemic heart disease. 
  • The impact of gender on the treatment and outcomes of patients with early reinfarction after fibrinolysis: insights from ASSENT-2. 
  • The management of acute coronary syndromes in patients with chronic kidney disease. 
  • The privilege of self-regulation: the role of appropriate use criteria. 
  • The relation between clinical features, angiographic findings, and the target lesion revascularization rate in patients receiving the endeavor zotarolimus-eluting stent for treatment of native coronary artery disease: an analysis of ENDEAVOR I, ENDEAVOR II, ENDEAVOR II Continued Access Registry, and ENDEAVOR III. 
  • The use of contrast-enhanced magnetic resonance imaging to identify reversible myocardial dysfunction. 
  • Therapeutic goals in patients with refractory chronic angina. 
  • Therapeutic value of eptifibatide at community hospitals transferring patients to tertiary referral centers early after admission for acute coronary syndromes. PURSUIT Investigators. 
  • Third universal definition of myocardial infarction. 
  • Transmyocardial laser revascularization limits in vivo adenoviral-mediated gene transfer in porcine myocardium. 
  • Transmyocardial laser revascularization: an anesthetic perspective. 
  • Transmyocardial laser revascularization: experimental and clinical results. 
  • Treatment of atrial fibrillation with concomitant coronary or peripheral artery disease: Results from the outcomes registry for better informed treatment of atrial fibrillation II. 
  • Treatment of persistent tachycardia with dexmedetomidine during off-pump cardiac surgery. 
  • Trends in Bare-Metal Stent Use in the United States in Patients Aged ≥65 Years (from the CathPCI Registry). 
  • Trends in quality of care for patients with acute myocardial infarction in the National Registry of Myocardial Infarction from 1990 to 2006. 
  • Trends in the use of evidence-based treatments for coronary artery disease among women and the elderly: findings from the get with the guidelines quality-improvement program. 
  • Troponin-T and N-terminal pro-B-type natriuretic peptide predict mortality benefit from coronary revascularization in acute coronary syndromes: a GUSTO-IV substudy. 
  • Troponin-positive, MB-negative patients with non-ST-elevation myocardial infarction: An undertreated but high-risk patient group: Results from the National Cardiovascular Data Registry Acute Coronary Treatment and Intervention Outcomes Network-Get With The Guidelines (NCDR ACTION-GWTG) Registry. 
  • Understanding thrombocytopenia and antigenicity with glycoprotein IIb-IIIa inhibitors. 
  • Unexplained international differences in clinical outcomes after acute myocardial infarction and fibrinolytic therapy: lessons from the Hirulog and Early Reperfusion or Occlusion (HERO)-2 trial. 
  • Utilization of early invasive management strategies for high-risk patients with non-ST-segment elevation acute coronary syndromes: results from the CRUSADE Quality Improvement Initiative. 
  • Variation in the use of stress testing and outcomes in patients with non-ST-elevation acute coronary syndromes: insights from GUSTO IIb. 
  • Viability assessment by delayed enhancement cardiovascular magnetic resonance: will low-dose dobutamine dull the shine? 
  • Vorapaxar in patients with peripheral artery disease and acute coronary syndrome: insights from Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRACER). 
  • Weighting composite endpoints in clinical trials: essential evidence for the heart team. 
  • [ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. The Task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC)]. 
  • [Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes]. 
  • β-Blocker use and clinical outcomes in stable outpatients with and without coronary artery disease. 
• 

  Keywords of People

  • Alexander, John Hunter Peel, Professor of Medicine, Medicine, Cardiology
  • Brennan, J. Matthew, Associate Professor of Medicine, Medicine, Cardiology
  • Granger, Christopher Bull, Professor of Medicine, School of Nursing
  • O'Connor, Christopher Michael, Adjunct Professor in the Department of Medicine, Medicine, Clinical Pharmacology
  • Patel, Uptal Dinesh, Adjunct Professor in the Department of Medicine, Medicine, Nephrology